Study registration: NCT04607941
Publication Charmet T, Lancet Reg Health Eu, 2021
Dates: 2020-12-27 to 2021-05-03
Funding: Public/non profit (Institut Pasteur, Research & Action Emerging Infectious Diseases (REACTing), Fondation de France (Alliance “Tous unis contre le virus”).)
Conflict of interest: no COI (All authors have nothing to declare.)

Methods

Study design:Case-control
Description of participants: Adults in France with or without prior history of infection (>2 months previous to index infection)
Inclusion criteria:
  • adults
  • diagnosed with COVID-19 between 14 February 2021 and 3 May 2021
  • with an email address with the national health insurance agency.
  • no documented recent SARS-CoV-2 infection.

Exclusion criteria:
  • NR

Follow-up duration (months): 4.25
Vaccines:
  • 1 or 2 doses
Variant description :
Variant name: Alpha
Evidence: Direct evidence (effectiveness determined by sequencing cases)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Yes
Data accessibility: The data that support the findings of this study are available from the Caisse Nationale d’Assurance Maladie, a national health insurance agency in France, and from Ipsos, a French market research and public opinion specialist company. Restrictions apply to the availability of these data, which were used under authorized agreement for this study by the data protection authority Commission Nationale de l’Informatique et des Libertes (CNIL). Access to these data would therefore require prior authorization by the CNIL.
General comment Concerns over self-reported intervention and confounding, selection of case and controls into the study and ascertainement of the outcome.